Reslizumab: First Global Approval

Drugs

Volumn 76, Issue 8, 2016, Pages 907-911

  Markham, Anthony ^a  

^a SPRINGER   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; RESLIZUMAB; IL5 PROTEIN, HUMAN; INTERLEUKIN 5; MONOCLONAL ANTIBODY;

ADD ON THERAPY; ANAPHYLAXIS; ASTHMA; CONTROLLED CLINICAL TRIAL (TOPIC); CREATINE KINASE BLOOD LEVEL; DRUG APPROVAL; DRUG EFFICACY; DRUG INDUCED CANCER; DRUG INDUSTRY; DRUG SAFETY; EOSINOPHILIC ESOPHAGITIS; HUMAN; INFUSION RELATED REACTION; LIMB PAIN; MAINTENANCE THERAPY; MUSCLE FATIGUE; MUSCLE SPASM; MUSCULOSKELETAL CHEST PAIN; MUSCULOSKELETAL PAIN; MYALGIA; NECK PAIN; NONHUMAN; OROPHARYNX PAIN; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; ADULT; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; EOSINOPHIL; FOOD AND DRUG ADMINISTRATION; UNITED STATES;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG APPROVAL; EOSINOPHILS; HUMANS; INTERLEUKIN-5; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84964443409     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-016-0583-2     Document Type: Review

References (11)

1. US Food and Drug Administration. FDA approves Cinquir to treat severe asthma [media release]. 23 Mar 2016. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm491980.htm.
2. Teva Respiratory LLC. Cinqair® (reslizumab) injection, for intravenous use: US prescribing information 2016. http://www.cinqair.com/. Accessed 8 Apr 2016.
3. Egan RW, Athwahl D, Chou CC, et al. Inhibition of pulmonary eosinophilia and hyperreactivity by antibodies to interleukin-5. Int Arch Allergy Immunol. 1995;107(1-3):321-2.
4. Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355-66.
5. Maspero J, Bjermer L, Lemiere C, et al. A randomized phase 3 study assessing patient-reported outcomes and safety of reslizumab in patients with asthma with elevated eosinophils. Ann Allergy Asthma Immunol. 2014;113(5 Suppl):A21.
6. Corren J, Weinstein S, Janka L, et al. Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest. 2016. doi: 10.1016/j.chest.2016.03.018.
7. Bernstein DI, Mansfield L, Zangrilli J. Efficacy of reslizumab in older patients (≥65 years) with asthma and elevated blood eosinophils: results from a pooled analysis of two phase 3, placebo-controlled trials [abstract no. 284]. J Allergy Clin Immunol. 2016;137(2 Suppl):AB86.
8. Brusselle G, Matthew G, Eid S. Reslizumab in patients with late-onset asthma with elevated blood eosinophils [abstract no. OA287]. Eur Respir J. 2015;46(Suppl 59):OA287.
9. Bjermer L, Lemiere C, Maspero J, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest. 2016. doi: 10.1016/j.chest.2016.03.032.
10. Murphy K, Jacobs J, Bjermer L. Long-term safety and efficacy of reslizumab in patients with inadequately controlled, moderate-to-severe asthma and elevated blood eosinophil counts: an open-label extension study [abstract no. 1025]. Am J Respir Crit Care Med. 2015;191:A6455.
11. Spergel JM, Rothenberg ME, Collins MH, et al. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2012;129(2):456-63.